iBio
IBIO
14 hedge funds and large institutions have $1.95M invested in iBio in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
24% less capital invested
Capital invested by funds: $2.58M → $1.95M (-$630K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$44.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.5K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$7.42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$11.1K |
| 2 |
Citigroup
New York
|
-$1K |
IBIO Hedge Fund Activity: Q3 2015 in Review
14 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2015, worth a combined $1.95M — down 24% from $2.58M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IBIO positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $51.9K. The largest seller was Northern Trust, cutting an estimated $11.1K.
- 14 institutional investors held iBio (IBIO) as of Q3 2015, up from 12 in Q2 2015.
- Funds reported $1.95M of iBio stock for Q3 2015, down 24% quarter-over-quarter.
- 2 funds opened new iBio positions in Q3 2015 and 0 closed out, a net change of +2 holders.
- The largest iBio buyer in Q3 2015 was Vanguard Group, an estimated $51.9K added.
- The largest iBio seller in Q3 2015 was Northern Trust, an estimated $11.1K sold.
Based on aggregated 13F filings for Q3 2015.